PFE Price Prediction Next Week
Based on the provided data and current market conditions, here's a comprehensive analysis for PFE's stock price prediction for the next trading week:
Technical Analysis
The technical indicators show PFE is currently trading at $26.07 with an RSI of 46.10, indicating a neutral momentum. The stock is trading below its 200-day SMA of $27.36, suggesting a bearish long-term trend. However, it's showing signs of stabilization around the current price level with Fibonacci support at $25.98.
News Sentiment Analysis
Several significant developments are likely to impact PFE's price movement:
Positive Clinical Results: PFE announced encouraging results from the Phase 3 BREAKWATER trial, showing a 61% objective response rate for its BRAFTOVI combination therapy. This positive development could provide upward momentum.
Settlement Impact: PFE's subsidiary Biohaven agreed to pay nearly $60 million to resolve false claims allegations. While negative, the settlement amount is relatively small compared to PFE's size and shouldn't significantly impact the stock.
Strong Shareholder Yield: PFE received a high rating of 85% from Validea's Shareholder Yield Investor model, indicating strong cash return to shareholders through dividends and buybacks.
Price Prediction for Next Week
Based on technical and fundamental factors:
Support Levels:
- Strong support: $25.70 (Fibonacci S2)
- Secondary support: $25.98 (Fibonacci S1)
Resistance Levels:
- First resistance: $26.90 (Fibonacci R1)
- Second resistance: $27.18 (Fibonacci R2)
Expected price movement: $26.40-$27.20
The stock is likely to trade in this range with an upward bias due to:
- Positive clinical trial results
- Strong shareholder yield metrics
- Technical indicators showing oversold conditions starting to reverse
Trading Recommendation: BUY with entry point at current levels ($26.07) or any dip towards $25.98. Set stop loss at $25.70 and first target at $26.90.
PFE Similar Chart Price Prediction
The price of PFE is predicted to go up -2.2%, based on the high correlation periods with TCBS. The similarity of these two price pattern on the periods is 94.27%.
PFE
TCBS
Down: -2.2%Similarity: 94.27%
PFE Stock Forecast & Prediction For Years 2025, 2026, 2028, 2029 and 2030
Year
PFE Price Forecast($)
Potential Return(%)
2025
26.730
0.530
2026
34.000
27.870
2028
40.000
50.430
2029
35.000
30.160
2030
40.000
48.750
What is PFE stock price prediction 2025 ?
What is PFE stock price prediction 2026 ?
What is PFE stock price prediction 2028 ?
What is PFE stock price prediction 2029 ?
What is PFE stock price prediction 2030 ?
PFE Revenue Forecast
PFE EPS Forecast
PFE FAQs
What is bull’s view on PFE?
What is bear's view on PFE?
What is PFE revenue forecast for next quarter？
What is PFE eps forecast for next quarter？
PFE VS S&P500
Pfizer's pipeline productivity is improving with several successful recent drug launches. In particular, cardiovascular drug Vyndaqel is a potential game-changer in the rare-disease arena.
Pfizer's strong success in developing a COVID-19 vaccine and treatment is yielding a massive cash windfall.
Pfizer's decision to divest its off-patent division should result in a faster-growing, innovative company.
PFE Analyst's Forecast
Colin Bristow
UBS
Hold
Price Target
$31 → $29
Upside
+7.97%
UBS lowered the firm's price target on Pfizer to $29 from $31 and keeps a Neutral rating on the shares as part of a broader note on the U.S. Pharmaceuticals and Biotechnology industry. The firm believes BioPharma will find it difficult to outperform against a more uncertain macro backdrop in the short-term, and thinks President-elect Trump will be capable of enacting significant legislative change, and that unpredictability is expected to cast a shadow over the space, the analyst tells investors in a research note. There will be continued uncertainty in the space until there is more clarity on Trump's changes, UBS says.
Tim Anderson
B of A Securities
Hold
Price Target
$29
Upside
+13.41%
Courtney Breen
Bernstein
Hold
Price Target
$32
Upside
+9.31%